Trending NewsTrending NewsTop-Rated StocksTop-RatedNASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $10.01 +0.81 (+8.75%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dyne Therapeutics Stock (NASDAQ:DYN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dyne Therapeutics alerts:Sign Up Key Stats Today's Range$9.32▼$9.9950-Day Range$8.18▼$14.7852-Week Range$6.36▼$47.45Volume794,722 shsAverage Volume2.55 million shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice Target$38.13Consensus RatingBuy Company Overview Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Read More Dyne Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreDYN MarketRank™: Dyne Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 206th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dyne Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted16.77% of the float of Dyne Therapeutics has been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 20.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.77% of the float of Dyne Therapeutics has been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 20.61%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.37 News SentimentDyne Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Dyne Therapeutics this week, compared to 7 articles on an average week.Search Interest3 people have searched for DYN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows9 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $911,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Stock News HeadlinesInsider Buying: Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO Acquires 100,000 Shares of StockJuly 16, 2025 | insidertrades.comDyne Therapeutics price target lowered to $23 from $25 at RBC CapitalJuly 29 at 12:44 PM | msn.comA $674B Industry Missed the Bigger PictureTV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.July 30 at 2:00 AM | Mode Mobile (Ad)Dyne Therapeutics Advances in Neuromuscular TherapiesJuly 29 at 7:42 AM | msn.comDyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsJuly 29 at 7:42 AM | finanznachrichten.deDyne Therapeutics extends cash runway as it advances key drug programsJuly 28 at 9:40 PM | za.investing.comDyne Reports Wider Loss in Fiscal Q2July 28 at 9:33 PM | fool.comDyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business HighlightsJuly 28 at 4:10 PM | globenewswire.comSee More Headlines DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $23.56 on January 1st, 2025. Since then, DYN stock has decreased by 61.0% and is now trading at $9.20. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) released its quarterly earnings results on Monday, July, 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.02. When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' top institutional shareholders include Aberdeen Group plc (0.43%), Mutual of America Capital Management LLC (0.04%), Compagnie Lombard Odier SCmA (0.02%) and 111 Capital (0.01%). Insiders that own company stock include Venture Fund Xi LP Atlas, Joshua T Brumm, John Cox, Oxana Beskrovnaya, Wildon Farwell, Jonathan Mcneill, Susanna Gatti High, Richard William Scalzo, Dirk Kersten, Johanna Friedl-Naderer and Carlo Incerti. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings7/28/2025Today7/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees100Year FoundedN/APrice Target and Rating Average Price Target for Dyne Therapeutics$38.13 High Price Target$66.00 Low Price Target$9.00 Potential Upside/Downside+314.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$317.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-61.80% Return on Assets-56.79% Debt Debt-to-Equity RatioN/A Current Ratio20.35 Quick Ratio20.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.19 per share Price / Book1.49Miscellaneous Outstanding Shares113,667,000Free Float90,058,000Market Cap$1.05 billion OptionableOptionable Beta1.08 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:DYN) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.